(CercleFinance.com) – Neovacs announced on Thursday an investment in Netri, a Lyon-based start-up that has developed organ-on-chip technology for the pharmaceutical industry.
The biotechnology company explains that it has decided to immediately invest two million euros in the company, with an option for an amount of up to an additional one million euros, subject to reaching objectives and according to the needs of the company.
Néovacs stresses that Netri’s technologies make it possible to create standardized and predictive ‘in vitro’ human models which make it possible to anticipate the efficacy of a treatment, while limiting the use of animal tests.
Current fields of application relate to neurological disorders, cosmetics and nutrition.
This is the fourth strategic investment made by Neovacs, and its third in a ‘biotech’ company.